Jerini AG expects to launch its treatment for acute attacks of hereditary angioedema (HAE), Icatibant, in Europe in the third quarter of 2008 following a positive opinion from the main scientific committee of the European Medicine Agency in April. The company expects to receive a marketing authorisation from the European Commission in late June or early July, a spokeswoman told MedNous.
